Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease by Jiang, Xuntian et al.




Neural stem cells for disease modeling and
evaluation of therapeutics for Tay-Sachs disease
Xuntian Jiang
Washington University School of Medicine in St. Louis
Daniel S. Ory
Washington University School of Medicine in St. Louis
et al
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Jiang, Xuntian; Ory, Daniel S.; and et al, ,"Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease."
Orphanet Journal of Rare Diseases.13,. 152. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7160
RESEARCH Open Access
Neural stem cells for disease modeling and
evaluation of therapeutics for Tay-Sachs
disease
Mylinh Vu1, Rong Li1, Amanda Baskfield1, Billy Lu1, Atena Farkhondeh1, Kirill Gorshkov1, Omid Motabar1,
Jeanette Beers2, Guokai Chen2,3, Jizhong Zou2, Angela J. Espejo-Mojica4, Alexander Rodríguez-López4,5,
Carlos J. Alméciga-Díaz4, Luis A. Barrera4, Xuntian Jiang6, Daniel S. Ory6, Juan J. Marugan1 and Wei Zheng1*
Abstract
Background: Tay-Sachs disease (TSD) is a rare neurodegenerative disorder caused by autosomal recessive mutations in
the HEXA gene on chromosome 15 that encodes β-hexosaminidase. Deficiency in HEXA results in accumulation of GM2
ganglioside, a glycosphingolipid, in lysosomes. Currently, there is no effective treatment for TSD.
Results: We generated induced pluripotent stem cells (iPSCs) from two TSD patient dermal fibroblast lines and further
differentiated them into neural stem cells (NSCs). The TSD neural stem cells exhibited a disease phenotype of lysosomal
lipid accumulation. The Tay-Sachs disease NSCs were then used to evaluate the therapeutic effects of enzyme
replacement therapy (ERT) with recombinant human Hex A protein and two small molecular compounds:
hydroxypropyl-β-cyclodextrin (HPβCD) and δ-tocopherol. Using this disease model, we observed reduction of
lipid accumulation by employing enzyme replacement therapy as well as by the use of HPβCD and δ-
tocopherol.
Conclusion: Our results demonstrate that the Tay-Sachs disease NSCs possess the characteristic phenotype to
serve as a cell-based disease model for study of the disease pathogenesis and evaluation of drug efficacy.
The enzyme replacement therapy with recombinant Hex A protein and two small molecules (cyclodextrin and
tocopherol) significantly ameliorated lipid accumulation in the Tay-Sachs disease cell model.
Keywords: Tay-Sachs disease, Induced pluripotent stem cells, Neural stem cells, Cyclodextrin, HPβCD, δ-
tocopherol, Enzyme replacement therapy, Hexosaminidase A, GM2 gangliosidosis, High throughput screening,
Drug discovery
Background
Tay-Sachs disease (TSD) is one of three lysosomal storage
diseases classified as GM2 gangliosidoses, along with
Sandhoff disease and the AB variant. TSD and Sandhoff
disease are caused by mutations in the HEXA and HEXB
genes, respectively. The AB variant is caused by mutations
in the GM2A gene encoding for the GM2 activator for
β-hexosaminidase A [1]. Both TSD and Sandhoff disease
are rare neurodegenerative disorders due to a deficiency
in the enzyme β-hexosaminidase, which hydrolyzes GM2
ganglioside into GM3 ganglioside. β-Hexosaminidase is a
heterodimer that exists in three isoforms: hexosaminidase
A (Hex A), hexosaminidase B (Hex B), and hexosamini-
dase S (Hex S). Hex A is an α/β heterodimer while Hex B
and Hex S consist of two β-subunits and two α-subunits,
respectively. In TSD patients, mutations in the HEXA
gene result in misfolded α-subunits that render Hex A
and Hex S non-functional [2]. Deficiency of Hex A activity
in TSD causes accumulation of GM2 ganglioside in
lysosomes, which ultimately results in progressive
neurodegeneration.
There are three forms of TSD: acute infantile, juvenile,
and adult. The variations of TSD are characterized by
the age of onset and level of remaining Hex A activity in
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patient cells [3]. Acute infantile TSD is the most com-
mon and harmful variant which shows progressive de-
cline in muscle strength and loss of motor skills around
six months to three years of age. As the disease pro-
gresses, the infant’s brain deteriorates which leads to sei-
zures, blindness, loss of cognitive functions, and
ultimately death [4].
Currently, there are no effective treatments for
Tay-Sachs disease. The main treatment approach involves
managing the symptoms of the disease [4]. Enzyme
replacement therapy (ERT) is available for treatment of
several lysosomal storage diseases such as Gaucher, Fabry,
and Pompe disease [5]. Treatment with recombinant hu-
man β-hexosaminidase in both human TSD fibroblasts
and mouse TSD models decreased lysosomal GM2 accu-
mulation [6, 7]. However, an earlier study failed to show
the beneficial effect of ERT in Tay-Sachs disease patients
[8]. Cyclodextrin (HPβCD) and δ-tocopherol have been
reported to reduce lipid accumulation and decrease the
enlarged lysosomes through increasing lysosomal exocyt-
osis [9]. We have observed the therapeutic effect of
HPβCD and δ-tocopherol in the induced pluripotent stem
cell (iPSC)-derived neural stem cells (NSCs) in NPC1,
NPA, Wolman, and Batten (CLN1 and CLN2) diseases
[9–13].
Recent advances in stem cell technology have enabled
the generation of disease-specific iPSCs from patient
somatic cells. These iPSCs can be differentiated into
various types of progenitor cells and mature cells such
as neurons, cardiomyocytes, hepatocytes, or retinal pig-
ment epithelial cells for modeling diseases in cell-based
assays [14, 15]. Due to the availability of large numbers
of NSCs derived from patient iPSCs and their disease
phenotypes, they have been used as a cell-based model
system for evaluating drug efficacy and drug develop-
ment [10, 11, 13]. In this study, we report the generation
of iPSC lines from two TSD patient dermal fibroblast
cells. These TSD iPSC lines were further differentiated
into NSCs that exhibited a disease phenotype of lipid
accumulation and enlarged lysosomes. The treatment of
these patient cells with recombinant human Hex A protein
dramatically reduced the lipid accumulation in the TSD
cells. δ-Tocopherol and hydroxypropyl-beta-cyclodextrin
(HPβCD) also ameliorated the lysosomal lipid accumula-
tion and decreased the enlargement of lysosomes in the
TSD NSCs. The results demonstrate that the TSD NSCs
differentiated from patient iPSCs are a useful disease model
for further study of disease pathophysiology and for use as
a cell-based model in drug development.
Methods
Materials
Three human dermal fibroblast cell lines were purchased
from the Coriell Cell Repositories (Camden, NJ): a wild
type female (catalog no. GM05659), a female TSD patient
(GM00515), and a male TSD patient (GM00221). See
Table 1 for details. DMEM medium (11965092), TrypLE
Express (12605010), penicillin-streptomycin (15140122),
sodium pyruvate (11360070), Essential 8 medium
(A1517001), PSC Neural Induction Medium kit
(A1647801), StemPro NSC SFM kit (A1050901), Human
neural stem cell immunocytochemistry kit (A24354),
CytoTune-iPS 2.0 Sendai Reprogramming Kit (A16517),
GlutaMax (35050), Hoechst 33342 (H3570), and Nile Red
(N1142) were obtained from Thermo Fisher Scientific.
Matrigel hESC-Qualified Matrix (354277) was obtained
from Corning. Rock Inhibitor Y-27632 (1254) was
obtained from Tocris Bioscience (Ellisville, MO). Hyclone
Fetal Bovine Serum (SH30071.03) was purchased from GE
Healthcare. δ-Tocopherol obtained from Sigma Aldrich
was further purified by HPLC to gain purity greater
than 99% while hydroxypropyl-beta-cyclodextrin (HPβCD,
E0163) was obtained from Roquette America (IL, USA).
Black, clear bottom, tissue-culture treated 96-well
plates (655090) were purchased from Greiner Bio-One
(Monroe, NC).
Generation and characterization of induced pluripotent
stem cells
Fibroblasts were cultured in DMEM medium with 15%
fetal bovine serum (FBS), 1X penicillin-streptomycin,
and 1X sodium pyruvate. Induced pluripotent stem cell
(iPSC) lines were generated from three fibroblast lines
using the non-integrating CytoTune-iPS 2.0 Sendai
Reprogramming Kit (Table 1). Two iPSC clones were
generated from each Tay-Sachs disease cell line. The
iPSCs were cultured on Matrigel pre-coated tissue cul-
ture plates using Essential 8 medium and passaged using
an EDTA-based protocol as previously described [16].
All iPSC lines were cultured beyond passage 10, to en-
sure the clearance of Sendai viruses and the stability of
the iPSC cell lines.
Short tandem repeat (STR) DNA analysis was per-
formed by Johns Hopkins University’s Genetic Resources
Table 1 Summary of human cell lines used in the study
Subject Fibroblast ID (Coriell) iPSC lines Gender Genotype
WT GM05659 HT268A Male Wild Type
Tay-Sachs GM00221 HT134A, E Male Homozygous-c.1278insTATC on exon 11 of HEXA gene
Tay-Sachs GM00515 HT151A, C Female Heterozygous-c.1278insTATC and Trp392Ter, both mutations on exon 11 of HEXA gene
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Core Facility on each set of TSD patient fibroblast cells
and NSC lines to confirm their identity as derivatives of
patient fibroblast lines GM00515 and GM00221.
G-banded karyotyping analysis of iPSCs was con-
ducted using standard cytogenetic protocol by WiCell
Research Institute (Madison, WI). The harvested iPSCs
were incubated with ethidium bromide and colcemid in
a hypotonic solution before being fixed. Twenty ran-
domly chosen cells in metaphase from each iPSC clone
were stained with Leishman’s stain and analyzed by
G-banding. The immunofluorescence staining and flow
cytometry were also used to characterize iPSCs gener-
ated. Immunocytochemistry assay was performed on
fixed iPSCs using the pluripotent cell markers of Sox2,
Oct4, Nanog, Tra-1-60, and SSEA4. Cells were imaged
using an INCell 2200 imaging system (GE Healthcare)
using 20X objective lens and Cy5, FITC, and DAPI filter
sets. For the FACS analysis, iPSCs were also harvested
and fixed using 4% paraformaldehyde and washed,
followed by a 10 min incubation with 0.2% Tween-20 to
permeabilize cell membrane. The cells were then stained
with anti-Tra-1-60-FITC and anti-Nanog-AlexaFluor
488. FACS was performed on a BD Accuri C6 Flow Cy-
tometry System.
Neural stem cell differentiation and characterization
Tay-Sachs disease iPSCs were differentiated into neural
stem cells (NSCs) using the PSC neural Induction
Medium kit (Thermo Fisher Scientific) according to the
manufacture’s protocol. Once iPSCs reached confluence
of 70 to 80%, cells were dislodged from plates using
0.5 mM EDTA buffer and seeded onto Matrigel coated
6-well plates at 3 × 105 cells/well in E8 medium with
10 μM of Rock Inhibitor Y-27632. Cells were incubated
overnight at 37 °C to attach onto the plate. The culture
media was then changed to PSC Neural Induction
Medium containing 1X Neural Induction Supplement in
Neurobasal Medium (Thermo Fisher Scientific). Media
was changed daily for 7 days. On the 7th day of neural
induction, the NSCs were dissociated from the plate
using Accutase enzyme cell detachment medium
(Thermo Fisher Scientific) and seeded into Matrigel
pre-coated T75 flasks for further expansion in the
Neural Expansion Medium containing 1X Neural Induc-
tion Supplement in equal volume of Neurobasal
Medium and Advanced DMEM/F-12 (Thermo Fisher
Scientific).
A Human Neural Stem Cell ICC kit (Thermo Fisher
Scientific) was used to characterize NSCs generated
from TSD patients and WT control iPSCs. The
anti-PAX6 antibody was replaced with Oct4 to verify
that the NSCs were no longer iPSCs. The manufacture’s
protocol was followed for the immunofluorescence
staining. Cells were then imaged in the INCell 2200
imaging system (GE Healthcare) using a 20X objective
lens with Cy5, FITC, and DAPI filter sets. Additionally,
Tay-Sachs disease NSCs were sent to the Johns Hopkins
University Genetic Resources Core Facility for STR
DNA profiling with the FAF’s PowerPlex 16D (Promega)
Standard Service Plus Profile Search.
Neuron differentiation and characterization
Tay-Sachs patient NSCs were further differentiated into
neurons using STEMdiff™ Neuron Differentiation Kit
and STEMdiff™ Neuron Maturation Kit (StemCell Tech-
nologies) according to the manufacture’s protocol. After
7 days of differentiation of Tay-Sachs NSCs to neuronal
precursors in 6- well plate using STEMdiff™ Neuron Dif-
ferentiation medium, cells were dislodged and seeded
into Poly-L-ornithine (PLO)/laminin coated black, clear
bottom, tissue-culture treated 96-well plate in STEM-
diff™ Neuron Maturation medium for another 7–14 days
before downstream application. Immunofluorescence
staining of several neuronal markers MAP2 (Cell signal-
ing), beta-III-tubulin (Cell signaling), Neurofilament-L
(Cell signaling) as well as Nestin (neural stem cell pro-
tein marker, BD Bioscience) were performed to
characterize the neuronal cells derived from TSD patient
and WT control NSCs.
Nile red assay
Nile Red dye stains the accumulated lipids and lipid
droplets in cells. It has been reported that the
yellow-gold fluorescence detects cytoplasmic lipid
droplets better than red fluorescence [11, 12, 17]. In
this experiment, the Nile Red dye staining was used to
evaluate the accumulation of lipids in TSD patient
NSCs, as well as neuronal cells. Briefly, cells were
seeded onto 96-well plates using the NSC maintenance
media from the StemPro NSC SFM kit with 5 μM Rock
Inhibitor. Plates with TSD NSCs were incubated over-
night at 37 °C and Rock Inhibitor was removed the fol-
lowing day. The assay media was replaced and 10% FBS
(Hyclone) was added to the medium followed by over-
night incubation at 37 °C to load the lipids into the
NSC cells. Assay media was then replaced to remove
the FBS, and plates were incubated again overnight at
37 °C for the Nile Red assay to be performed the fol-
lowing day. Nile Red powder was reconstituted in
DMSO to 1 mM and stored in the dark at − 20 °C until
used. In the Nile Red staining assay, the stock solution
was diluted to 1 μM in warmed assay media and incu-
bated with cells for 10 mins in the dark at 37 °C. The
cells were then washed twice using Dulbecco’s
phosphate-buffered saline (DPBS) and fixed in 4% para-
formaldehyde for 30 min at room temperature. Hoechst
was also added to the fixing step using a 1:5000 dilu-
tion. After washing twice with DPBS, 200 μl/well DPBS
was added before analyzing in the INCell 2200 imaging
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system using a 20X objective lens with TR/TR, FITC/
YFP, and DAPI/DAPI filter sets.
LysoTracker Red dye staining
TSD NSCs were seeded and treated with FBS in the
same way as described above. For the LysoTracker dye
staining, the NSCs were treated with 50 nM LysoTracker
Red DND-99 dye (L-7528, Thermo Fisher Scietific) in
assay media at 37 °C for 1 h followed by plate washing
twice with DPBS. The plates were fixed and stained with
Hoechst simultaneously in 4% paraformaldehyde solu-
tion with Hoechst dye at a 1:5000 dilution for 30 min at
room temperature. Plates were washed twice using
DPBS and stored with 100 μl/well DPBS at 4 °C until
imaging. Images were acquired using the INCell 2200
imaging system using a 20X objective lens with Texas
Red and DAPI filter sets.
Filipin staining
Filipin dye was used to stain unesterified cholesterol in
cells [18]. Cells were seeded at 2000 cells/well in 100 μl
of media in black, clear bottom, tissue culture-treated
96-well plates and cultured for 24 h. The test com-
pounds were dissolved in media and then added at
100 μl /well; the cells were returned to incubation for
4 days. The cells were washed twice with DPBS and
fixed with 100 μl/well of 4% paraformaldehyde (PFA)
solution at room temperature for 30 min. After washing
twice with DPBS, the cells were stained with 50 ng/mL
Filipin solution (freshly dissolved in DMSO at 10 mg/
mL and then diluted in DPBS) at room temperature for
1 h. The plates were stored in 100 μl/well DPBS at 4 °C
after washing two times with DPBS before imaging ana-
lysis. On the day of the imaging, cell nuclei were stained
with 100 μl/well of 4 μM ethidium homodimer (EthD-1)
(Thermo Fisher Scientific) in DPBS at room temperature
for 30 min. The plates were imaged using the INCell
2200 imaging system with a 20X or 40X objective lens.
A DAPI filter set (excitation = 350 ± 50 nm, and emis-
sion = 455 ± 50 nm) and Cy3 filter set (excitation = 543 ±
22 nm, and emission = 604 ± 64 nm) were used to
visualize Filipin and EthD-1 staining, respectively.
GM2 ganglioside immunofluorescence staining
For immunofluorescence staining of GM2, same FBS
treatment protocol was used as for the Nile Red staining
experiment prior to the staining. Briefly, 10% FBS was
added to the assay medium followed by overnight incu-
bation to load the lipids into the cells. Assay media was
then replaced to remove the FBS, and plates were incu-
bated again overnight at 37 °C for the GM2 immuno-
fluorescence staining to be performed the following day.
Cells were fixed in 4% paraformaldehyde for 30 min,
rinsed with PBS, and permeabilized with 0.3% Triton
X-100 for 15 min at 4 °C. Cells were incubated with nor-
mal goat serum 10% blocking buffer (Life Technologies)
and incubated with mouse anti-GM2 antibody (Amsbio,
clone MK1–16) overnight at 4 °C. After washing with
PBS, a corresponding secondary antibody conjugated
with Alexa Fluor 594 was added. Cells were then stained
with Hoechst 33342 for 20 min and imaged using an
INCell Analyzer 2200 imaging system (GE Healthcare)
with 20X objective lens and Texas Red and DAPI filter
sets.
LC-MS/MS analysis of GM2 in TSD NSCs
We further utilized the LC-tandem mass spectrometry
(LC-MS/MS) analysis to determine the GM2 content in
TSD patient cells following the protocol established previ-
ously [19]. Briefly, TSD patients and WT control neural
stem cell pellets were collected and suspended in 50 μL of
water. The ganglioside GM2 was extracted from cell sus-
pension with protein precipitation with methanol in the
presence of internal standard (d3-GM2 (18:0)). The gan-
glioside GM2 was separated by column-switching
high-performance liquid chromatography (HPLC) and
monitored by multiple-reaction monitoring (MRM) detec-
tion on an Applied Biosystems Sciex 6500QTRAP+ tan-
dem mass spectrometer (MS/MS) equipped with an
electrospray ion source. A quality control (QC) sample
was prepared from pooled study samples and injected
every 3 study samples to monitor the LC-MS/MS assay
performance. All the ganglioside GM2 species in QC in-
jections demonstrate CV < 15%. The protein precipitate
from extraction was dissolved in a mixture of 2% CHAPS
(100 μL) and 1% SDS (750 μL), and the protein was mea-
sured with BCA assay. The relative quantification data
were provided as area ratios of GM2 species to internal
standard, which were normalized to the protein.
Recombinant β-hexosaminidases production in Pichia
pastoris GS115
Recombinant Hex A was produced in the methylo-
trophic yeast Pichia pastoris GS115 as previously de-
scribed [20]. Briefly, cDNA of α- (GenBank AAH84537)
and β- (GenBank AAH17378) subunits of human
β-hexosaminidases were codon-optimized for P. pas-
toris and inserted into a pPICK9k vector. Constructs
pPIC9k-alpha or pPIC9k-beta were co-transformed into
P. pastoris GS115. Clones were evaluated at a shake
flask scale, and that with highest activity was used for
production of recombinant human Hex A (rhHexA).
Cultures were prepared in a modified FM22 saline
media and protein production conditions were per-
formed as previously described [20, 21].
Recombinant protein was purified from culture media
thanks to the presence of the α-factor secretion signal,
and purified by ion exchange chromatography as
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previously described [20]. β-Hexosaminidase activity was
assayed by using 4-methylumbelliferyl-β-D-acetyl-glucosami-
nide (MUG, Sigma-Aldrich) or 4-methylumbelliferyl-
β-D-acetyl-glucosaminide sulfate (MUGS, Calbiochem)
substrates [20, 22]. One unit (U) was defined as the
amount of enzyme hydrolyzing 1 nmol of substrate per
hour. Specific hexosaminidase activity was expressed as
U/mg of total protein determined by a Lowry assay.
Enzyme replacement therapy
TSD NSCs were seeded onto 96-well plates pre-coated
with Matrigel using the NSC maintenance media formu-
lated from the StemPro NSC SFM kit containing 5 μM
Rock Inhibitor. Plates were incubated at 37 °C overnight
and the medium was changed the following day to
remove Rock Inhibitor; 100 nM of Hex A recombinant
enzyme was incubated with TSD NSCs for 4 h at 37 °C
in NSC maintenance media. The media was changed to
remove excess recombinant enzymes not taken up by
the cells and other components in the buffer of enzyme
stock that are not suitable for neural stem cell culture.
Because the neural stem cell culture medium does not
containing serum and regular lipid components, 10%
FBS was added to the medium to facilitate lysosomal
storage of lipids. Therefore, we added the enzyme first
and wash the cells 4 h later to replace with the medium
containing 10% FBS for cell culture overnight. NSCs
were cultured in NSC maintenance medium with or
without 10% FBS for 24 h at 37 °C. The Nile Red dye
staining was performed on the following day.
Treatments with HPβCD and δ-tocopherol
On Day 0, TSD NSCs and wild type NSCs were seeded into
96-well plates pre-coated with Matrigel in 100 μl/well of
NSC maintenance media from the StemPro NSC SFM kit
along with 5 μM Rock Inhibitor. The plates were incubated
overnight at 37 °C. The media was changed the next day
(Day 1) to remove Rock Inhibitor. The cells were treated
with HPβCD and δ-tocopherol at 37 °C for 24 h. On Day 2,
the medium was replaced with NSC maintenance medium
containing 10% FBS and HPβCD or δ-tocopherol followed
by incubation at 37 °C for another 24 h. HPβCD was dis-
solved in water while δ-tocopherol was dissolved in
DMSO to a 100 mM stock. The Nile Red dye staining was
performed on Day 3 of the experiment.
ATP content assay for cell viability
An ATP content assay kit (ATPLite, PerkinElmer) was used
to measure cell viability to monitor compound cytotoxicity.
Cells were seeded at 2500 cells/well in 100 μl medium in
white, solid 96-well plates and incubated for 24 h. Cells
were cultured and treated as described above. After 3 days
of incubation, 100 μl/well of ATP content reagent mixture
(prepared according to the manufacturer’s instruction) was
added to the assay plates followed by incubation at room
temperature for 2–5 min. The luminescence signal was de-
termined in the luminescence mode of the ViewLux Plate
reader (PerkinElmer).
Data analysis and statistics
Image analysis of Nile Red staining, LysoTracker Red
staining, and Filipin staining was performed using
INCell Analyzer software (GE Healthcare, version 3.7.2).
The Multi-Target Analysis protocol was used for quanti-
fication of all three assays. Concentration-response
curves were analyzed and IC50 values calculated using
the Prism software (GraphPad, Inc., San Diego). Results
in the figures were expressed as mean of replicates ±
standard error of the mean (SEM). Unless otherwise
stated, an unpaired t-test was used to test for signifi-
cance, with * p < 0.05, ** p < 0.01, and *** p < 0.001.
Results
Generation and characterization of Tay-Sachs iPSCs
Tay-Sachs iPSC lines were generated from two Tay-Sachs
patient dermal fibroblasts obtained from Coriell Cell
Repositories (GM00221 and GM00515) using the
non-integrating Sendai virus reprogramming system
that expresses Oct3/4, Sox2, Klf4, and c-Myc factors
(Table 1). A patient iPSC line HT134A was established
from the fibroblast line GM00221, while another patient
iPSC line HT151A was generated from GM00515
(Table 1). No obvious differences in iPSC morphology
(Additional file 1: Figure S1A) or growth rate were
observed in the TSD iPSC lines compared to the wild
type (WT) cells. Flow cytometry analysis showed that
the iPSCs expressed the pluripotency markers of TRA-1-60
and Nanog (Fig. 1b, Additional file 1: Figure S1B).
Immunofluorescence staining experiments showed
positive staining of major pluripotency markers in-
cluding nuclear markers (SOX2, Oct4, Nanog) and
stem cell-specific cell surface markers (TRA-1-60 and
SSEA4) (Fig. 1a, Additional file 1: Figure S1A). Further-
more, G-banding karyotyping analysis confirmed the normal
karyotype in the TSD iPSC (Additional file 1: Figure S2B).
The short tandem repeat (STR) profiling analysis confirmed
the cell source of each iPSC line as all 11 checked STR loci
matched with its parental Tay-Sachs patient fibroblasts
(Additional file 1: Figure S2C). The results demonstrate the
successful generation of two TSD iPSC lines.
Generation and characterization of Tay-Sachs disease
neural stem cells
The TSD iPSCs and WT iPSCs were then differentiated into
NSCs using the commercial PSC Neural Induction Medium.
The NSCs exhibited normal morphology and no significant
differences were observed in the differentiation time and cell
morphology of patient cells compared to the WT control
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cells. Immunofluorescence staining of major NSC
markers demonstrated that the NSCs differentiated
from TSD iPSC lines expressed high level of NSC
markers SOX1, SOX2, and Nestin, but not Oct4, a
pluripotency marker only expressed in iPSCs (Fig. 1c,
Additional file 1: Figure S1C).
TSD NSCs exhibited lipid accumulation in lysosomes and
enlarged lysosomes
To examine the lipid accumulation in lysosomes, a Nile
Red dye staining assay was used for visualizing nonpolar
lipid in the patient cells [9]. Both TSD NSC lines
(HT134A and HT151A) showed increased Nile Red dye
Fig. 1 Characterization of Tay-Sachs disease iPSCs and NSCs. a The iPSCs derived from TSD patients and WT control fibroblasts expressed pluripotency
protein markers SOX2, Oct4, Nanog, TRA-1-60 and SSEA4. b Flow cytometry analysis of TSD iPSCs, > 94% of iPSCs expressing Nanog and TRA-1-60 markers.
c Immunofluorescence staining of TSD and WT NSCs. Nestin, SOX1, and SOX2 are neural stem cell markers while Oct4 is an iPSC marker
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staining, indicating accumulation of lipids in lyso-
somes after loading with lipids in FBS for 24 h
(Fig. 2a, Additional file 1: Figure S3A and 3B). In
comparison to WT NSCs, the Nile Red staining in
NSC HT134A and HT151A lines was two-fold. (Fig.
2c). These results indicated a significant accumulation
of nonpolar lipid in both TSD patient iPSC-derived
NSCs.
To determine whether the lysosomes were enlarged
in those TSD patient cells due to the accumulation of
lipid, LysoTracker Red dye staining was also carried
out to visualize enlarged lysosomes. A sight increase
of lysotracker staining in TSD patient NSCs com-
pared to the NSCs derived from WT control iPSCs.
In contrast, the NSCs derived from Niemann-Pick
disease, type C1 (NPC1) iPSCs showed much stronger
Lysotracker fluorescence signal (Fig. 2b, Additional
file 1: Figure S3A and 3C), consistent with our previ-
ous findings [9, 13, 23].
To evaluate the potential secondary accumulation of
other lipids inside the cells, we further carried out the
Filipin staining for unesterified cholesterols that accu-
mulates in the lysosomes of many patient cells with lyso-
somal storage diseases, especially the Niemann Pick
disease type C. The Filipin staining was not significantly
different in all four TSD patient iPSC-derived NSCs
compared to the WT NSCs (Additional file 1: Figure
S5), indicating an absence of lysosomal accumulation of
unesterified cholesterol in these TSD patient cells.
Together, these results revealed a disease phenotype of
significant increase in lipid accumulation in both TSD
NSC lines differentiated from patient iPSCs. Thus, these
Fig. 2 Nile Red and LysoTracker Red staining of TSD NSCs. a Images of increased intensity of Nile Red staining in TSD NSC compared to WT NSCs
after 24 h addition of 10% FBS. The yellow/gold fluorescence of Nile Red excites and emits at 450-500 nm and 528 nm, respectively. b
LysoTracker Red staining in TSD NSCs. c Intensity of Nile Red staining in TSD NSCs after FBS treatment. d Intensity of LysoTracker Red staining in Tay-Sachs
disease NSCs after FBS treatment. Data are displayed as mean ± SD. **** p< 0.0001 compared to WT control. IxA, integrated cell intensity
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patient NSCs may serve as a cell-based disease model to
study disease pathology to evaluate drug efficacy.
GM2 ganglioside accumulation in TSD NSCs
To examine the accumulation of GM2 gangliosides in
TSD patient cells, immunofluorescence staining of GM2
were carried out. No significant difference was observed
in both TSD patient NSCs compared to the WT control
(Additional file 1: Figure S4A and 4C).
GM2 profiling was further performed with LC-MS/MS
analysis. In contrast to the immunofluorescence staining
data, LC-MS/MS analysis showed significant elevation of
GM2 levels in both TSD patient cell lines (NSC HT134A
and NSC HT151A) compared to the WT control NSCs
(Fig. 3).
Recombinant human Hex A reduced lipid accumulation in
TSD NSCs
To further validate this cell-based disease model, we
evaluated the effect of recombinant human Hex A pro-
tein on rescuing the disease phenotype of TSD NSCs.
Treatment of NSCs with 100 nM Hex A significantly re-
duced Nile Red dye staining in TSD NSC lines (HT134A
and HT151A) (Fig. 4). Nile Red dye staining in both
NSC lines of HT134A and HT151A was reduced to a
low level similar to WT cells, indicating significant re-
duction of lipid accumulation in lysosomes. These re-
sults demonstrate that recombinant Hex A treatment
rescued the disease phenotype in the TSD NSCs.
δ-Tocopherol and HPβCD reduced lipid accumulation in
TSD NSCs
δ-Tocopherol and HPβCD have been reported to signifi-
cantly reduce lysosomal accumulation of cholesterol and
decrease the enlargement of lysosomes in NPC1 and
NPA cells [10, 13, 23]. The positive effects of
δ-tocopherol were previously observed in the TSD fibro-
blasts [9]. Here, we examined the effects of δ-tocopherol
and HPβCD on lipids accumulated in TSD NSCs using
the Nile Red dye staining. We found that both
compounds reduced Nile Red dye staining in a
dose-dependent manner (Figs. 5 and 6). The half
maximal effective concentration (EC50) values of
δ-tocopherol were 14.5 μM in HT134A and 10.9 μM in
HT151A lines. Treatment with 20 μM δ-tocopherol dis-
played a 75% and 83% decrease of Nile Red staining
compared to the untreated patient cell lines, HT134A
and HT151A, respectively (Fig. 5b). Treatment with
500 μM HPβCD dramatically reduced the Nile Red dye
staining to a level similar to WT NSCs, with a 97% re-
duction in the TSD HT134A line and a 92% decrease in
the HT151A line. The EC50 values for TSD NSCs treated
with HPβCD were 183.8 μM in cell line HT134A and
261.1 μM in cell line HT151A (Fig. 6b). Together, the re-
sults demonstrate that δ-tocopherol and HPβCD signifi-
cantly ameliorated the lipid accumulation in the TSD
NSCs.
To improve the therapeutic effect and reduce the drug
concentrations needed to achieve the maximal response,
a combination therapy of both δ-tocopherol and HPβCD
was also tested. This combination showed a significantly
decrease of lipid accumulation in TSD NSCs (Fig. 7). A
combination of 50 μM HPβCD and 5 μM δ-tocopherol,
both at lower concentrations than either one alone, was
effective in reducing lipid accumulation. At these con-
centrations (50 μM of HPβCD and 5 μM of δ-tocopherol),
no significant reduction of lipid accumulation was observed
when either compound was used alone. The combination
of 5 μM δ-tocopherol and 50 μM HPβCD significantly de-
creased lipid accumulation to levels comparable to WT
cells, suggesting a synergistic effect (Fig. 7a, b). Addition-
ally, an ATP content assay confirmed the cell viability from
different experimental groups (Fig. 7c).
Neuronal cell differentiation from Tay-Sachs iPS cells
We further differentiated TSD NSCs and WT NSCs into
neuronal cells. Immunofluorescence staining of major
neuronal cell makers demonstrated that the neuronal
cells differentiated from TSD and WT NSCs lines
expressed high levels of neuronal cell protein markers
MAP2, ß-III-Tubulin, Neurofilament-L, but not Nestin
(a protein marker of neural stem cells). (Fig. 8a). The re-
sults provide evidence for the generation of TSD neu-
rons from patient NSCs cells.
Fig. 3 LC-MS/MS analysis of GM2 profile in TSD NSCs. The relative
quantification data were provided as area ratios of GM2 species to
internal standard, which were normalized to the protein level.
Significant elevation of GM2 level was detected in TSN NSCs compared
to the WT NSCs. All samples were run in the same batch. Data are
displayed as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, compared
to the WT control
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Nile Red staining and LysoTracker Red staining were
carried out to evaluate the lipid accumulation and lyso-
some enlargement in TSD neurons. However, we only
observed a small, but not significant increase of both
Nile Red fluorescence signal (Fig. 8b) and lyso-
Tracker Red staining signal (Fig. 8c) in one of the patient
cell lines, HT131A, but not in HT151 patient line com-
pared to the WT control neurons.
Discussion
δ-Tocopherol and HPβCD had been reported to signifi-
cantly reduce lysosomal accumulation of cholesterol and
decrease the enlargement of lysosomes in NPC1 and
NPA cells [10, 13, 23].
Recent advances in iPSC technology have enabled the
generation of patient iPSC lines from skin fibroblasts
and other cells such as peripheral blood mononuclear
Fig. 4 Effect of hexosaminidase A (Hex A) on lipid accumulation in TSD NSCs. a Nile Red staining of NSC HT134A and NSC HT151A after 4 h
incubation with Hex A. b Normalized percent Nile Red IxA of TSD NSCs after treatment with Hex A. Nile Red IxA values of TSD NSCs treated with
HexA were normalized to untreated TSD NSCs as 100% and Nile Red IxA of WT NSCs as 0%. Data are mean ± SEM (n = 30), **** p < 0.0001,
compared to each other. IxA, integrated cell intensity
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cells (PBMCs). These patient-derived iPSC are
self-renewable and can be differentiated to many cell
types previously hard to obtain including neuronal cells,
cardiomyocytes, and hepatocytes [13, 24–28]. Neural
stem cells can self-renew and also exhibit the characteris-
tic disease phenotype of several lysosomal diseases in-
cluding Niemann Pick disease type C (NPC),
NPA and Wolman disease [10, 11, 13]. Other groups
have also employed patient iPSC-derived NSCs or neu-
rons to study disease pathogenesis and phenotypes such
as neuropsychiatric diseases [27]. Those patient-derived
cells have also been used as cell-based disease models to
evaluate drug efficacy and phenotypic high throughput
screening (HTS) to identify new lead compounds for
drug discovery [10, 11, 13] [29].
In this study, we have successfully generated two
Tay-Sachs disease patient iPSC lines and further differenti-
ated them into NSCs that exhibit a characteristic disease
phenotype of lysosomal lipid accumulation. GM2 is the
primary lipid accumulated in the Tay-Sachs’ patient cells
[2]. However, we found that the immunostaining with
anti-GM2 antibodies did not reveal difference between the
patient cells and wild type control cells. This might be due
to the issue with specificity of commercially available
GM2 antibodies that are not sensitive enough for the im-
munostaining experiment. Further study using MS
Fig. 5 Reduction of lipid accumulation in TSD NSCs after treatment with δ-tocopherol. a Nile Red staining of NSC HT134A and HT151A after 48 h
of treatment with δ-tocopherol ranging from 0 to 20 uM. b Normalized percent IxA of TSD NSCs after treatment with δ-tocopherol (n = 40; SEM).
Nile Red IxA of TSD NSCs treated with δ-tocopherol were normalized to IxA of untreated TSD NSCs set as 100% and IxA of WT NSCs set as 0%.
IxA, integrated cell intensity
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method confirmed the accumulation of GM2 lipid in the
patient cells. However, the GM2 measurement using MS
method requires a significant amount of resources and
cells without the high-throughput necessary for com-
pound screening.
In addition to GM2 ganglioside buildup, secondary
accumulation of other lipids including phospholipids,
cerebrosides, sphingomyelin, and cholesterol have been
reported [30]. Nile Red is a hydrophobic and meta-
chromatic dye, which yields fluorescence varying from
deep red to strong yellow-gold depending on the hydro-
phobicity of the lipid environment [17]. In this study, we
found that the increased Nile Red dye staining in TSD
patient NSCs could be rescued by recombinant human
Hex A protein. Thus, these patient cells can be used as a
cell-based disease model and Nile Red staining offers a
valid method for evaluating drug efficacy and compound
screening. The significant lipid accumulation was not
observed in the patient iPSC-derived neurons in our ex-
periments. It could be due to a lack of neuronal matur-
ation. The images of LysoTracker Red and Nile Red
staining in neurons also exhibited high variability in in-
dividual cells, indicating that the current method may
not be sensitive enough for neuronal detection. Currently,
production of large amount of neurons is still a bottleneck
for compound screening assays. The reproducibility of
Fig. 6 Reduction of lipid accumulation in TSD NSCs after treatment with HPβCD. a Nile Red staining of TSD NSC HT134A and HT151A after 48 h
treatment with HPβCD ranging from 0 to 500 uM. b Normalized percent Nile Red IxA of TSD NSCs after treated with HPβCD (n = 40; SEM). Nile Red IxA
of HPβCD treated TSD NSCs were normalized to untreated TSD NSCs IxA as 100% and WT NSCs IxA as 0%. IxA, integrated cell intensity
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iPSC-differentiated neurons from batch to batch can not
be easily controlled. Therefore, we have used the NSCs
[9–12] as a model system for evaluation of compound effi-
cacy and compound screening because NSCs can be pro-
duced in large quantities with good reproducibility.
Previously, ERT for TSD was tested in clinical trials
through intraventricular delivery and injections into the
spinal canal. However, no reduction of GM2 ganglioside
accumulation was detected in patients due to the limited
amount of the enzyme that was able to reach neural cells
[8]. In this study, we found that patient NSCs treated
with Hex A exhibited decreased lipid accumulation (Fig.
4). It has been reported that just 10% of normal activity
of Hex A is required for patients to be characterized as
WT [31]. Therefore, only a small amount of Hex A ac-
tivity is needed to ameliorate the disease phenotype.
Even though ERT has proven to be an effective treat-
ment in several other lysosomal storage disorders like
Gaucher disease, and Pompe diseases, ERT is not feas-
ible for TSD [5] because recombinant Hex A cannot
cross the blood-brain barrier (BBB) and therefore cannot
be effective for neurological symptoms [8]. The recom-
binant enzyme may be directly administrated into brain
via intrathecal or intraparenchymal injection. But the
procedure is invasive and usually not suggested as the
best route of treatment due to its high safety risks and
costs [32, 33]. Furthermore, ERT for lysosomal storage
diseases generally requires frequent administration [34].
Nonetheless, ERT should be further investigated and
developed for patients with TSD to ameliorate symptoms
in the peripheral body such as muscle weakness, spasm,
and paralysis. New technologies and methods are needed
Fig. 7 Combination treatment of HPβCD and δ-tocopherol reduces lipid accumulation in TSD NSCs. a Nile Red staining images of TSD NSCs compared to
WT NSCs following compound combination treatment. b Nile Red IxA of NSC HT134A and HT151A after 48 h incubation with HPβCD and δ-tocopherol.
c Cell viability of TSD NSCs after compound combination treatment. * p< 0.5, *** p< 0.001 compared to untreated control. # p< 0.05, ### p< 0.001
compared to each other. IxA, integrated cell intensity
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for efficient and safe delivery of recombinant Hex A pro-
tein into the brain. One of the methods currently under
study is using ultrasound to temporarily increase the
permeability of the BBB, as well as decreasing the efflux
of transporters to allow more passive diffusion of hydro-
phobic compounds [35]. Additionally, liposomes and
their polymer analog, polymerosomes, have been used in
conjugation with ligands or polymer chains that allow
for specific drug delivery across the BBB [33, 35] and
enable ERT for lysosomal storage diseases with neuro-
logical effects.
We also evaluated two small molecules, HPβCD
and δ-tocopherol, using the TSD patient NSCs. Both
compounds effectively reduced lipid accumulation in
TSD NSCs. However, a much higher concentration of
HPβCD is needed to reduced lipid accumulation in
TSD cells compared to NPC1 NSCs [13]. The con-
centration of HPβCD can be significantly reduced
when it was used in combination with δ-tocopherol.
It has been reported that both δ-tocopherol and
HPβCD decrease cholesterol accumulation in NPC1
cells by inducing lysosomal exocytosis [9, 36]. Al-
though the exact mechanisms of action for both
δ-tocopherol and HPβCD in TSD NSCs are unclear,
it is possible that there is a synergistic effect when the
two compounds are used as a combination therapy.
Fig. 8 Neuronal cell differentiation from Tay-Sachs iPSCs. a Immunofluorescence staining of TSD and WT neurons. MAP2, β-III-tubulin and
Neurofilament-L are neuronal cell protein markers while Nestin is a neural stem cell marker, serving as the negative control. b Nile red staining on
TSD and WT neurons. c LysoTracker red staining on TSD and WT neurons. No significant increase of Nile red staining or LysoTracker red staining
was observed in TSD neurons compared to the WT control cells. Data are displayed as mean ± SD. * p < 0.05, compared to the WT control. IxA,
integrated cell intensity
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Conclusions
Two lines of iPSCs have been generated from TSD patient
fibroblasts, and the NSCs derived from these TSD iPSCs
exhibit the disease phenotype of lipid accumulation in ly-
sosomes. ERT with recombinant Hex A protein rescues
the disease phenotype in the TSD NSCs. HPβCD and
δ-tocopherol also reduce the lysosomal lipid accumulation
in patient-derived NSCs. Overall, our data demonstrate
that the patient-derived NSCs can be used as a cell-based
disease model to study disease pathology and perform
compound screening for drug development.
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